TREATMENT AND DIAGNOSTIC USING miRNA, PROTEIN AND GENE BIOMARKERS USING QUANTUM DOT FIELD-EFFECT TRANSISTOR (FET) SENSOR PLATFORM

• US 20180120254A1
• Filed: 07/24/2017
• Published: 05/03/2018
• Est. Priority Date: 07/22/2016
• Status: Active Application

• Current Assignee: Anjana Jain
• Original Assignee: Anjana Jain
• Inventors: Jain, Anjana
• Application Number:
  US15/657,809
• Publication Number:
  US 20180120254A1
• Time in Patent Office: Days
• CPC Class Codes: C12Q 1/6825 Nucleic acid detection involving sensors
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/178 miRNA, siRNA or ncRNA
• CPC Class Codes: G01N 27/4145 specially adapted for biomolecules, e.g. gate electrode with immobilised receptors
• CPC Class Codes: G01N 27/4146 involving nanosized elements, e.g. nanotubes, nanowires
• CPC Class Codes: G01N 2800/28 Neurological disorders
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/5438 Electrodes
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: G01N 33/588 with semiconductor nanocrystal label, e.g. quantum dots
• CPC Class Codes: H01L 29/1025 Channel region of field-effect devices
• CPC Class Codes: H01L 29/127 Quantum box structures
• CPC Class Codes: H01L 29/495 the conductor material next to the insulator being a simple metal, e.g. W, Mo H01L29/4908, H01L29/4983 take precedence

Abstract

An array of biosensors diagnosing biomarkers device and a drug delivery vehicle system including a plurality of biosensor arrays for diagnosing biomarkers concentrations, and a delivery vehicle dispensing drug, a electronic interface, a plurality of algorithms to relate biomarker concentrations and drug dispensed, wherein biosensors in said plurality of biosensor arrays are constructed from quantum dot field-effect transistors, and wherein one or more layers of cladded quantum dots are assembled in the channel, gate, and channel and gate regions of FETs, and wherein quantum dots are functionalized by DNA aptamers, antisense oligoneuclotides (ASOs), and DNAs, to sense biomarkers concentrations comprising at least one of proteins, miRNAs, and genes, and wherein the concentrations of biomarkers changes and their values change the magnitude of drain current as a function of time, and wherein the drain current signal is processed by an electronic interface.

Claims

1. A method of diagnosing biomarkers and delivering a drug, wherein the biomarkers are comprising of proteins, miRNAs, antisense oligoneuclotides (ASOs), DNA/genes, the method comprising:

diagnosing biomarkers, wherein diagnosing is performed by detecting biomarker concentrations as a function of time in at least one of a body fluid and tissue, and

wherein biomarker concentrations are determined by a plurality of biosensors, and wherein at least one of the plurality of biosensors include quantum dot based field-effect transistor sensing elements having quantum dots, wherein the quantum dots are functionalized to sense concentrations of at least one of proteins, miRNAs, ASOs, DNAs and genes, and

wherein the biomarker concentration changes the drain current in a proportionate manner, and

wherein the changed current proportional to biomarker concentration information is signal processed outside the body using body fluids, or using implanted biosensors where the signal is transmitted via wires transcutaneously or wireless via a RF or optical transmitter to an external unit to display the biomarker levels, and

wherein quantum dots are disposed in one of transport channel region, gate region, gate and transport channel regions, and

wherein quantum dots are functionalized with recognition elements comprising protein aptamers, ASO strands, RNA and DNA strands, and wherein respective biomarkers bind, and

wherein drug comprises at least one or more of proteins, anti-sense oligoneuclotides (ASOs), genes and DNAs, and

wherein dosage of drugs are based on concentration of proteins and ASOs which up and down regulate concentration of proteins, miRNAs and DNA levels in body fluids and tissues at designated sites, and

wherein a nanocarrier vehicle is used to load the drug, and

wherein the nanocarrier vehicle is one selected from Si nanofibers, SiOx-coated Si nanowires, polymer nanofibers, re-absorbable nanofibers, and

wherein nanofibers are functionalized to deliver ASOs, proteins, miRNAs and their combinations.

2. The method of claim 1, further comprising aptamers, wherein the aptamers are used to detect protein biomarkers related to Alzheimer and traumatic brain injury.

3. The method of claim 1, where an algorithm is used to develop concentrations of various constituents of a combination of ASOs, miRNAs and protein to up and down regulate levels of proteins and miRNAs.

4. An array of biosensors diagnosing biomarkers device and a drug delivery vehicle system comprising:

a plurality of biosensor arrays for diagnosing biomarkers concentrations, and

a delivery vehicle dispensing drug,

a electronic interface,

a plurality of algorithms to relate biomarker concentrations and drug dispensed,

wherein biosensors in said plurality of biosensor arrays are constructed from quantum dot field-effect transistors, and wherein one or more layers of cladded quantum dots are assembled in the channel, gate, and channel and gate regions of FETs, and

wherein quantum dots are functionalized by DNA aptamers, antisense oligoneuclotides (ASOs), and DNAs, to sense biomarkers concentrations comprising at least one of proteins, miRNAs, and genes, and wherein the concentrations of biomarkers changes and their values change the magnitude of drain current as a function of time, and

wherein the drain current signal is processed by an electronic interface, and wherein first algorithm determines the concentrations of various biomarkers, and

wherein delivery vehicle comprises one or more of nanoparticles, SiOx-Si quantum dots, polymer quantum dots and metallic quantum dots, and

wherein nanoparticles and quantum dots are assembled on nanofibers,

and wherein nanofibers are selected from polymer, silicon nanowires, quartz, metal and ceramic, and

wherein assembled SiOx-Si quantum dots on nanofibers and functionalized with drug comprising of one or more selected from proteins ASOs, DNAs and genes, and

wherein the combination of ASOs, miRNAs, proteins, and genes is based on second algorithm, and wherein the said combination is drug that administered at a site, and

wherein concentration of biomarkers after a time interval is measured by another set of array of biosensors diagnosing biomarkers device using freshly functionalized quantum dot array FETs, and where in a new cycle of measurements of biomarker concentrations and drug delivery vehicle follows.

5. The device of claim 4, further comprising,

arrays of quantum dot FET biosensors for diagnosing cancer biomarkers, and wherein a electronic interface and first algorithm determines the concentrations and their time variations of biomarkers comprising proteins, miRNAs, genes, and

wherein nanocarrier delivery vehicle dispensing drug dose comprising one or more selected from proteins, ASOs, miRNAs, and genes, and wherein the drug dose is determined by a second algorithm and,

wherein site to administer nanocarrier delivery vehicle is determined by the second algorithm, and

wherein biomarker concentrations are determined at a later time after a time interval and compared by said electronic interface with the previous concentrations, and

wherein the nanocarrier delivery vehicle drug dose is adjusted to maintain biomarker levels, and

wherein nanocarrier drug dose is dispensed using micropumps, and

wherein micropumps are controlled by said electronic interface and its associated microprocessor.